Health
Immunotherapy combination shrinks rare angiosarcoma tumors in 25% of patients – News-Medical.Net
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute’s Division of Cancer Diagnosis and Treatment,…
Reviewed by Emily Henderson, B.Sc.Nov 15 2020
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute’s (NCI) Division of Cancer Diagnosis and Treatment (DCTD), part of the National Institutes of Health, have shown that the immunotherapy combination of ipilimumab and nivolumab shrinks rare angiosarcoma tumors in 25 percent of all patients, with some having an even stronger response to the drug combination.
Results of the SWOG study, led…
-
General12 hours agoVictorian school teacher charged with soliciting child abuse material
-
Business21 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business23 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
Business20 hours agoHere’s what analysts expect for the BHP share price in the coming year